Menu
Recruiting NCT07012486

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

Early Phase I Interventional Androgenetic Alopecia (AGA)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Oral DHA + Topical minoxidil 5%, Topical Minoxidil 5%.
Who it may be relevant to
Registry conditions: Androgenetic Alopecia (AGA). Basic parameters: 18 years — 40 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia

Overview

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.

Interventions

  • Drug Oral DHA + Topical minoxidil 5%
    DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
  • Drug Topical Minoxidil 5%
    Topical minoxidil 5% daily for 180 days

Primary outcome measures

  • Improvement in terminal hair follicles in the vertex area [Time frame: Baseline and 180-day of treatment]
Secondary outcome measures (5)
  • Change of terminal hair follicle density in the vertex area from baseline to the end of treatment [Time frame: Baseline and 180-day of treatment]
  • Change of hair density in the vertex area from baseline to the end of treatment [Time frame: Baseline and 180-day of treatment]
  • Change of terminal hair follicle density in the frontal area from baseline to the end of treatment [Time frame: Baseline and 180-day of treatment]
  • Change of hair density in the frontal area from baseline to the end of treatment [Time frame: Baseline and 180-day of treatment]
  • Change of serum total testosterone from baseline to the end of treatment [Time frame: Baseline and 180-day of treatment]

Eligibility criteria

Inclusion criteria

  • Clinically diagnosed with androgenetic alopecia (AGA)
  • No pregnancy plans within the next 6 months

Exclusion criteria

  • Patients who received systemic medications for hair loss within the past 2 months
  • Use of topical medication for hair loss within the past 2 weeks
  • Pregnancy or lactation
  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Zhongshan Hospital Fudan University — Shanghai

Identifiers

NCT: NCT07012486 · B2025-112R

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗